MeVis Medical Solutions AG (FRA:M3V) EBIT: €1.61 Mil (TTM As of Mar. 2026)


FRA:M3V MeVis Medical Solutions AG FRA:M3V
66 GF Score
Price €23.20
GF Value €22.52
! 4 Warning Signs
View Full Analysis

What is MeVis Medical Solutions AG EBIT?

MeVis Medical Solutions AG FRA:M3V 66 EBIT is €1.61 Mil as of Mar. 2026. GuruFocus rates FRA:M3V with a GF Score™ of 66/100 and a GF Value™ of €22.52. The stock has 4 warning signs investors should review.

MeVis Medical Solutions AG's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was €0.02 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €1.61 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. MeVis Medical Solutions AG's annualized ROC % for the quarter that ended in Mar. 2026 was 0.18%. MeVis Medical Solutions AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 11.94%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. MeVis Medical Solutions AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.09%.


MeVis Medical Solutions AG  (FRA:M3V) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

MeVis Medical Solutions AG's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=0.036 * ( 1 - 7.03% )/( (19.081 + 18.769)/ 2 )
=0.0334692/18.925
=0.18 %

where

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

MeVis Medical Solutions AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0.036/( ( (0.309 + max(-3.955, 0)) + (0.294 + max(-0.675, 0)) )/ 2 )
=0.036/( ( 0.309 + 0.294 )/ 2 )
=0.036/0.3015
=11.94 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.514 + 0 + 0.251) - (3.472 + 0 + 2.248)
=-3.955

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.984 + 0 + 0.265) - (0.744 + 0 + 2.18)
=-0.675

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

MeVis Medical Solutions AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=1.607/39.303
=4.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MeVis Medical Solutions AG EBIT Related Terms


MeVis Medical Solutions AG EBIT Historical Data

* Premium members only.

The historical data trend for MeVis Medical Solutions AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MeVis Medical Solutions AG EBIT Chart

MeVis Medical Solutions AG Annual Data
Trend Dec15 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.64 7.88 5.08 4.71 3.28

MeVis Medical Solutions AG Semi-Annual Data
Jun16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.30 2.40 1.69 1.59 0.02

FRA:M3V vs VEEV, BTSG, TEM: EBIT Comparison

For the Health Information Services subindustry, MeVis Medical Solutions AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MeVis Medical Solutions AG EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, MeVis Medical Solutions AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MeVis Medical Solutions AG's EV-to-EBIT falls into.


FRA:M3V
66GF Score
MeVis Medical Solutions AG FRA:M3V
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MeVis Medical Solutions AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €1.61 Mil mean?
MeVis Medical Solutions AG (FRA:M3V) has a EBIT of €1.61 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on MeVis Medical Solutions AG.
Is MeVis Medical Solutions AG's EBIT too high?
MeVis Medical Solutions AG's current EBIT is €1.61 Mil. Overall, MeVis Medical Solutions AG has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does MeVis Medical Solutions AG's EBIT compare to VEEV and BTSG?
MeVis Medical Solutions AG's EBIT of €1.61 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on MeVis Medical Solutions AG. MeVis Medical Solutions AG's current EBIT is €1.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeVis Medical Solutions AG stock overvalued right now?
MeVis Medical Solutions AG (FRA:M3V) has a current EBIT of €1.61 Mil. The stock's GF Value™ is €22.52, compared to a current price of €23.20 — trading 3% above its estimated fair value. The current EBIT is €1.61 Mil. MeVis Medical Solutions AG's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For MeVis Medical Solutions AG (FRA:M3V), the current EBIT is €1.61 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MeVis Medical Solutions AG (FRA:M3V) Overvalued in 2026?

Based on GuruFocus' analysis, MeVis Medical Solutions AG stock appears to be overvalued. The current stock price of €23.20 is trading 3% above its estimated GF Value™ of €22.52.

Key valuation signals for FRA:M3V:

  • EBIT: €1.61 Mil
  • GF Value™: €22.52 vs. price of €23.20 (3% above fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the FRA:M3V stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MeVis Medical Solutions AG Business Description

Other Exchanges 0HI7:UKM3V:Germany
Address Caroline-Herschel-Strasse 1, Bremen, DEU, 28359
MeVis Medical Solutions AG is a provider of medical software products. The company markets its products to equipment manufacturer of medical devices and providers of medical information technology platforms. Its segment includes Digital mammography and Other diagnostics. The Digital mammography segment develops and markets software products which assist in breast diagnostic imaging and intervention. Its Other diagnostics segment consists of digital radiology products. In addition, it also provides the general analysis of radiology images. The company's geographical area of operations includes the United States of America and Europe.
66GF Score

Get the complete analysis for FRA:M3V

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€23.20
Price
€22.52
GF Value